| Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ... New England Journal of Medicine 385 (25), 2348-2360, 2021 | 656 | 2021 |
| Homologous and heterologous Covid-19 booster vaccinations RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ... New England Journal of Medicine 386 (11), 1046-1057, 2022 | 528 | 2022 |
| Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant KE Lyke, RL Atmar, CD Islas, CM Posavad, D Szydlo, RP Chourdhury, ... Cell Reports Medicine 3 (7), 2022 | 153 | 2022 |
| Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City D Landman, P Kelly, M Bäcker, E Babu, N Shah, S Bratu, J Quale Journal of Antimicrobial Chemotherapy 66 (2), 332-334, 2011 | 104 | 2011 |
| Heterologous SARS-CoV-2 booster vaccinations–preliminary report RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ... MedRxiv, 2021 | 96 | 2021 |
| Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration D Landman, E Babu, N Shah, P Kelly, O Olawole, M Bäcker, S Bratu, ... Journal of antimicrobial chemotherapy 67 (6), 1427-1431, 2012 | 93 | 2012 |
| Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients RJ Ulrich, AB Troxel, E Carmody, J Eapen, M Bäcker, JA DeHovitz, ... Open forum infectious diseases 7 (10), ofaa446, 2020 | 80 | 2020 |
| Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City D Landman, E Babu, N Shah, P Kelly, M Bäcker, S Bratu, J Quale Journal of antimicrobial chemotherapy 65 (10), 2123-2127, 2010 | 76 | 2010 |
| Recurrent intravascular-catheter-related bacteremia caused by Delftia acidovorans in a hemodialysis patient K Chotikanatis, M Bäcker, G Rosas-Garcia, MR Hammerschlag Journal of clinical microbiology 49 (9), 3418-3421, 2011 | 56 | 2011 |
| Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City J Quale, N Shah, P Kelly, E Babu, M Backer, G Rosas-Garcia, J Salamera, ... Microbial Drug Resistance 18 (2), 132-136, 2012 | 55 | 2012 |
| Susceptibility Profiles, Molecular Epidemiology, and Detection of KPC-Producing Escherichia coli Isolates from the New York City Vicinity D Landman, C Urban, M Bäcker, P Kelly, N Shah, E Babu, S Bratu, ... Journal of clinical microbiology 48 (12), 4604-4607, 2010 | 38 | 2010 |
| SARS-CoV-2 variant vaccine boosters trial: preliminary analyses AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... MedRxiv, 2022.07. 12.22277336, 2022 | 36 | 2022 |
| Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... Nature medicine 29 (9), 2334-2346, 2023 | 21 | 2023 |
| Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants KE Lyke, RL Atmar, C Dominguez Islas, CM Posavad, ME Deming, ... Npj Vaccines 8 (1), 98, 2023 | 15 | 2023 |
| Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials DA Theodore, AR Branche, L Zhang, DS Graciaa, M Choudhary, ... JAMA network open 6 (7), e2323349-e2323349, 2023 | 15 | 2023 |
| Response of human immunodeficiency virus lymphomas to highly active anti-retroviral therapy without chemotherapy: report of four patients and literature review G Sidhu, J Delury, J Sanmugarajah, C Axiotis, M Backer, AS Braverman Leukemia & lymphoma 50 (12), 2089-2100, 2009 | 8 | 2009 |
| Risk of COVID-19 after natural infection or vaccination AM Rick, MB Laurens, Y Huang, C Yu, TCS Martin, CA Rodriguez, ... EBioMedicine 96, 2023 | 7 | 2023 |
| Membrane-bound SIV envelope trimers are immunogenic in ferrets after intranasal vaccination with a replication-competent canine distemper virus vector X Zhang, O Wallace, KJ Wright, M Backer, JW Coleman, R Koehnke, ... Virology 446 (1-2), 25-36, 2013 | 6 | 2013 |
| Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial AR Branche, NG Rouphael, C Losada, LR Baden, EJ Anderson, ... Clinical Infectious Diseases 77 (4), 560-564, 2023 | 5 | 2023 |
| Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial A Branche, N Rouphael, D Diemert, A Falsey, C Losada, LR Baden, ... Research Square, 2023 | 5 | 2023 |
